Empagliflozin selected cardiovascular and safety outcomes in routine care: First results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Abstract
Background: EMPRISE studies the effectiveness, safety and healthcare utilization of empagliflozin (EMPA), sodium-glucose cotransporter-2 inhibitor, using data from Medicare and two U.S. commercial claims datasets (2014–2019). Methods: In an analysis on data from 2014-2016, we identified 17,551 pairs of 1:1 propensity score-matched patients ≥18 years with Type 2 diabetes initiating EMPA or a dipeptidyl peptidase-4 inhibitor (DPP4i). We assessed a...
Paper Details
Title
Empagliflozin selected cardiovascular and safety outcomes in routine care: First results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Published Date
Mar 1, 2020
Journal
Volume
104
Pages
154126 - 154126
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History